Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $64.45

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been given a consensus rating of “Buy” by the fourteen brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $64.45.

MAZE has been the subject of several research reports. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright reissued a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a report on Thursday, September 24th. Wedbush restated an “outperform” rating and set a $48.00 target price on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday, September 21st. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Tuesday, September 22nd.

Maze Therapeutics Trading Up 0.1%

Maze Therapeutics stock opened at $31.73 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics has a one year low of $21.95 and a one year high of $53.65. The stock has a market capitalization of $1.76 billion, a PE ratio of -12.59 and a beta of 2.16. The business’s fifty day moving average is $27.40 and its 200 day moving average is $32.08.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). On average, sell-side analysts predict that Maze Therapeutics will post -2.70 EPS for the current year.

Insider Buying and Selling at Maze Therapeutics

In other news, CEO Jason Coloma sold 34,501 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $27.02, for a total transaction of $932,217.02. Following the completion of the sale, the chief executive officer owned 15,558 shares of the company’s stock, valued at $420,377.16. The trade was a 68.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $27.06, for a total value of $202,950.00. Following the completion of the sale, the insider owned 32,316 shares of the company’s stock, valued at $874,470.96. This trade represents a 18.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 185,491 shares of company stock worth $4,947,034. 5.30% of the stock is currently owned by insiders.

Institutional Trading of Maze Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. raised its stake in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the period. TRV GP IV LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $133,502,907. ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics during the 2nd quarter valued at about $122,983,582. BlackRock Inc. bought a new position in shares of Maze Therapeutics during the 2nd quarter valued at approximately $104,525,000. Finally, Jupiter Topco LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter valued at approximately $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.